Healthy ConsolidationIdeally we break 5.28 before we start to consolidate, (maybe failed attempt on the gap up open tomorrow) and finish the week between 4.57 and 4.67. Then when Weed reports results that show improvement like ACB even if they won't be the best, we could run another 30% to test the 6$ level. If Weed results don't provide momentum like ACB results, we will have to be patient until Aphria reports Q4. Ideal scenario is that Aphria share price is as high possible before Aphria Q4 so we test again the early january level (8.00$) and break it with conviction because we should except a considerable improvement based on Irwin comments during the conference call even if they removed guidance. I just hope there's no bad surprise with CC pharma revenues.
Worst case scenario we will have to wait Q1 2021 to see the edibles take full effect and have Aphria use EU GMP certification at Aphria One to ship product to Europe and have CC pharma do the distribution.
Good luck